Literature DB >> 33607999

Icariin promotes the repair of PC12 cells by inhibiting endoplasmic reticulum stress.

Chengjie Wu1,2, Guanglu Yang1,2, Yalan Pan3, Lei Wang1, Pengcheng Tu1,2, Suyang Zheng1, Yang Guo4,5, Yong Ma6,7.   

Abstract

BACKGROUND: Endoplasmic reticulum stress (ERS) is one of the main mechanisms of spinal cord injury (SCI) pathology and can affect the physiological state of neurons. Icariin (ICA), the main pharmacological component of Epimedium, can relieve the symptoms of patients with SCI and has obvious protective effects on neurons through ERS.
METHODS: PC12 cells were induced to differentiate into neurons by nerve growth factor and identified by flow cytometry. Cell proliferation was detected by CCK8 method, cell viability was detected by SRB assay, apoptosis was detected by flow cytometry and microstructure of ER was observed by transmission electron microscope. Western blot was used to detect the protein expression of CHOP and Grp78, and qPCR was used to detect the mRNA expression of CHOP and Grp78.
RESULTS: The results of CCK8, SRB and flow cytometry showed that ICA could relieve ERS and reduce apoptosis of PC12 cells. The results of transmission microscope showed that ICA could reduce apoptosis of PC12 cells caused by ERS. The results of Western blot and q-PCR showed that ICA could inhibit ERS by down-regulating the expression of CHOP and Grp78.
CONCLUSIONS: ICA can inhibit ERS and promote the repair of PC12 cells by down-regulating the expression of CHOP and Grp78. ICA has the potential to promote the recovery of spinal cord injury.

Entities:  

Keywords:  CHOP; Endoplasmic reticulum stress; Grp78; Icariin; Neuron

Year:  2021        PMID: 33607999     DOI: 10.1186/s12906-021-03233-1

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  1 in total

1.  [Icariin alleviates lipid peroxidation after spinal cord injury in rats].

Authors:  Xian-Sheng Ren; Wei Ding; Xiao-Yu Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.